NEXGEL, Inc. (NXGLW) Stock Analysis

Company Overview

NEXGEL, Inc. functions as a specialized manufacturer and seller of high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels designed for applications in wound care, medical diagnostics, transdermal drug delivery, and cosmetics within the United States. The company operates through two distinct segments, specifically identified as Nexgel and CG labs, to deliver its portfolio of medical and cosmetic gel products. As a private entity listed under the ticker NXGLW, the company reports a market capitalization that is not publicly disclosed in the available financial data, alongside an annual revenue of $11.67 million and a workforce of 19 employees. The combination of a modest employee base and the absence of a reported market cap indicates that NEXGEL operates on a micro-cap scale, reflecting a niche position in the healthcare materials sector where the company focuses on specific polymer technologies rather than broad-scale industrial manufacturing.

Financial Health

The company's financial performance over the trailing twelve months is characterized by a total revenue of $11.67 million, which contrasts sharply with a net income loss of $2,880,000 and an EBITDA loss of $2,533,000. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure where operating expenses and losses heavily outweigh gross profits, resulting in a net loss that is nearly equal to the EBITDA loss. This financial profile is further reflected in the free cash flow, which stands at -$1,494,875, indicating that the company is currently burning cash and lacks the immediate financial flexibility to fund operations without external capital injection. The company's profitability is constrained by negative margins across the board, with a gross margin of 40.8%, an operating margin of -24.7%, and a profit margin of -24.7%. While the gross margin suggests that the core production of hydrogels retains a healthy portion of revenue before overhead, the negative operating and profit margins demonstrate that selling, general, and administrative costs are consuming the majority of the gross profit. On the liability side, the company holds $938,000 in cash against a total debt load of $3.19 million, resulting in a debt-to-equity ratio of 57.24 which highlights a highly leveraged balance sheet. Despite the high leverage, the current ratio of 1.69 indicates that the company maintains adequate short-term liquidity to cover its current liabilities with its current assets. Finally, the return metrics show a return on equity of -52.8% and a return on assets of -16.8%, revealing that management is currently generating negative returns on both shareholder equity and the total asset base due to the prevailing operational losses.

Valuation Assessment

The valuation metrics for NEXGEL, Inc. are incomplete regarding earnings multiples, as the trailing twelve-month P/E ratio and the forward P/E are both unavailable due to the company's negative earnings. The absence of a forward P/E implies that the market cannot apply traditional earnings-based growth expectations to the stock until the company achieves positive profitability. Instead, the price-to-book ratio is available at 0.11, which indicates that the company's market capitalization is trading at a significant discount to its book value, suggesting a deep value or distressed valuation profile. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also not available in the current dataset, limiting the ability to compare NEXGEL against peers using revenue or enterprise value multiples. The stock price has shown no volatility within the reporting period, with the 52-week high and 52-week low both recorded at $0.07, meaning the current price sits exactly at the 52-week high and low. This stagnant price action, combined with a beta of 0.62, suggests that the stock's price volatility is less than 38% of the broader market's volatility, indicating a lower sensitivity to general market movements.

Growth & Income

The growth profile of the company is currently contracting, as evidenced by a revenue growth rate of -0.2% year-over-year, while earnings growth is unavailable due to the negative earnings position. The negative revenue growth indicates that the company's top line is flat or declining, and since net income is negative, there is no earnings growth trajectory to analyze for the current period. NEXGEL, Inc. does not pay a dividend, evidenced by the unavailable dividend yield and payout ratio figures, which means the company reinvests its limited cash flow or raises capital to sustain operations rather than returning value to shareholders. The overall growth and income profile is characterized by a lack of dividend income and a contraction in revenue, presenting a scenario where the company relies entirely on capital markets or cash reserves to fund its research and development of hydrogel technologies while navigating a period of financial contraction.